Latigo Biotherapeutics
LTGO
15.52
-0.74
-4.55%
Latigo Biotherapeutics
US · LTGO
#3230 by market cap
Listed 2026
15.52
-0.74
-4.55%
Live - 5344 symbols - heartbeat 261s ago
· 2026-10-07 19:54
After-hours
15.89
+2.38%
- Market cap
- 1.03B
- P/E (TTM)i
- -9.26
- P/Bi
- -3.73
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on LTGO?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 6.67M | 10.86M |
| Research & development | 56.78M | 99.53M |
| Operating profit | -63.45M | -110.39M |
| Pretax profit | -61.18M | -109.17M |
| Tax | -- | -- |
| Net profit | -61.18M | -109.17M |
| Basic EPS | -1 | -2 |
| Diluted EPS | -1.39 | -2.48 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 2.82M | 2.82M | 5.80M | 4.58M |
| Research & development | 18.69M | 22.92M | 17.63M | 21.23M |
| Operating profit | -21.51M | -25.75M | -23.44M | -25.81M |
| Pretax profit | -20.95M | -25.84M | -22.96M | -25.80M |
| Tax | -- | -- | -- | -- |
| Net profit | -20.95M | -25.84M | -22.96M | -25.80M |
| Basic EPS | 0 | -1 | -1 | 0 |
| Diluted EPS | -0.48 | -0.59 | -0.52 | -0.43 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 21.16M | 73.83M |
| Cash & ST investments | 17.92M | 69.44M |
| Inventory | -- | -- |
| Total assets | 22.86M | 75.52M |
| Total current liabilities | 14.44M | 18.45M |
| Short-term debt | 387.00K | 563.00K |
| Long-term debt | -- | -- |
| Total liabilities | 152,463,000.00 | 307,190,000.00 |
| Total equity | -129.60M | -231.67M |
| Retained earnings | -133.96M | -243.13M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 46.84M | 59.20M |
| Cash & ST investments | -- | -- | 42.18M | 55.00M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 50.58M | 64.76M |
| Total current liabilities | -- | -- | 14.49M | 51.58M |
| Short-term debt | -- | -- | 502.00K | 30.60M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 303,160,000.00 | 340,840,000.00 |
| Total equity | -- | -- | -252.58M | -276.08M |
| Retained earnings | -- | -- | -266.09M | -291.89M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -50.96M | -97.56M |
| Depreciation & amortization | 244.00K | 249.00K |
| Free cash flow | -51.03M | -97.69M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | 337.00K | 0 |
| Ending cash balance | 17.92M | 69.72M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -21.16M | -21.56M | -27.07M | -21.28M |
| Depreciation & amortization | 67.00K | 66.00K | 47.00K | 52.00K |
| Free cash flow | -21.26M | -21.59M | -27.07M | -21.39M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 96.09M | 74.50M | 42.42M | 55.21M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -267.60 | -221.93 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 1.47 | 4.00 |
| Quick ratioi | 1.24 | 3.76 |
| Debt / assetsi | 3.72 | 0.91 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -- | -- | -219.80 | -171.62 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 3.23 | 1.15 |
| Quick ratioi | -- | -- | 2.91 | 1.07 |
| Debt / assetsi | -- | -- | 1.10 | 48.26 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.